Clinical Trial Search

Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population

Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71

Primary: Percentage of Whole Body Lean Mass (%WBLM) — 67.3; 61.9 % of whole body mass

Primary: Stool Calories During OF and UF — 5.8; 8.9 percentage of calorie intake

Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants

Primary: Evaluation of the Changes in Microbiome Species Abundance and Diversity From Baseline Until End of Study (Day 35) — 27.00; 31.25; 27.00; 27.00 copies/ng DNA — p=<0.0001

Primary: Evaluation of the Levels of B.Infantis in Stool by Quantitative PCR — 3.33; 3.33; 3.33; 3.33 copies/ng DNA — p=<0.0001

Primary: Gut Microbiota Composition — 58; 30; 0.04; 7.3 percentage of bacterial phyla

Primary: Change in Mean Number of Colonic Submucosal Neurons/mm^2 in the Colon After Antibiotic Treatment — 0 neuronal cells/mm^2

Primary: Within Participant Variability in Microbiome Composition by Treatment Phase — 0.165; 0.175; 0.210 weighted unifrac distrance

Primary: Golimumab Induced Shifts in the Abundance of Bacterial Markers — 14965109899; 132857054401767; 12779328208; 12851286145 16S gene copies per gram of faeces

Primary: Clinical Response — 9 Participants — p=0.03

Primary: To Evaluate the Effect of BSS on the Human Gut Microbiome. — 2 Number of different bacterial taxa — p=<0.05

Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants

Primary: Percent Change From Baseline in Insulin Resistance Based on Insulin-Stimulated Glucose Uptake (M) During Hyperinsulinemic Euglycemic Clamp — -3; 5 percent change — p=0.16

Primary: Microbiome Analysis: Alpha Diversity — 4.89 Shannon index

Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events

Primary: Changes in Diversity of Gut Microbiota 16S rRNA Gene Sequences With Regard to Time. — 316.383; 302.400; 283.058 Avg. Operational Taxonomic Units

Primary: Change in Microbial Phylum Abundance (% of Total) Between Spice and Placebo — 65.1; 65.9; 58.7; 70.1 percentage of total bacteria — p=0.033

Primary: The Composition of Bacteria Present, Established by Ultra-deep RNA Gene Sequencing, in Pre-morbid Faecal Samples From Neonates With Necrotizing Enterocolitis and…

Primary: Stool Short-chain Fatty Acids Production Following Each Intervention Between Mothers and Daughters — 50; 26; 41.7; 47.8 umol/g

Primary: Bacteria Prevalence in Stool — 22.3; 20.9; 18.0; 25.5 percentage of bacterial genera in stool — p=<0.05

Primary: Change in Interleukin-6 (Value at Week 8 Minus Value at Week 0) — 0.35; -1.08; 0.51 pg/mL — p=0.9942

Primary: Differential Gene Expression in Gut Epithelium — 29; 6 Differentially expressed gene

Primary: Change in Microbiota, as Measured by Change in Microbiota Composition, Including Presence of B. Adolescentis BD1 and B. Animalis Supsp Lactis BB-12 — 7.9; 9.1; 8.8; 6.0…

Primary: Insulin Sensitivity — 10.16; 8.45; 9.47; 5.96 M Value (mg/kg/min) — p=<0.025

Primary: Change in the Gut Microbiome Profile — 818.5; 229; 1610; 177 species count

Primary: Composition of the Fecal Microbiota — 42; 12; 1.1; 14 percentage of total bacteria — p=<0.01

Primary: Mean Composite PROMIS Maximum Scores — 4.3; 5.0; 3.0; 4.4 score on a scale

Primary: Mucosal Surface Enlargement — 10.2; 9.9 percentage of muscular mucosae — p=<0.05